Alembic Pharmaceuticals zooms on getting final nod for Ketorolac Tromethamine Injection

Alembic Pharmaceuticals is currently trading at Rs. 661.55, up by 49.35 points or 8.06% from its previous closing of Rs. 612.20 on the BSE.

alembic pharmaceuticals gets usfda approval for solifenacin succinate tablets
Alembic Pharmaceuticals

The scrip opened at Rs. 608.70 and has touched a high and low of Rs. 675.00 and Rs. 603.55 respectively. So far 143890 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 847.95 on 04-Jan-2022 and a 52 week low of Rs. 541.10 on 20-Oct-2022.

Last one week high and low of the scrip stood at Rs. 675.00 and Rs. 548.00 respectively. The current market cap of the company is Rs. 12802.16 crore.

The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 17.87% and 12.52% respectively.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection USP, 15 mg/mL, 30 mg/mL, and 60 mg/2 mL (30 mg/mL) Single Dose Vials.

This is the second injectable product approval from company’s General Sterile Facility (F-3) which was inspected in August, 2022.

Ketorolac Tromethamine Injection USP has an estimated market size of $59 million for twelve months ending June 2022 according to IQVIA.

The company has a cumulative total of 175 ANDA approvals (151 final approvals and 24 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Leave a Comment